Crestor less safe than competing statins
Researchers announced that in a head-to-head study, the cholesterol-lowering drug Crestor had more side effects than Lipitor, Zocor, or Pravachol, though it remained generally safe to take. The researchers reviewed reports of 145 adverse events, including kidney and muscle damage, for Crestor out of 5 million prescriptions. ''Although (Crestor) was found to be less safe than others, it does not mean patients should immediately stop taking this medication," the lead author of the study, Dr. Richard H. Karas, stated in a release. ''In fact, the overall risks of (Crestor) remain low." An earlier FDA review of AstraZeneca's Crestor found it equally safe as other statins.
- read this story from the Boston Globe for more on the study
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


